Characterization and treatment of persistent hepatocellular secretory failure

Liver International

Volumn 35, Issue 4, 2015, Pages 1478-1488

  van Dijk, Remco ^a   Kremer, Andreas E ^a,b   Smit, Wouter ^a   van den Elzen, Bram ^a   van Gulik, Thomas ^a   Gouma, Dirk ^a   Lameris, Johan S ^a   Bikker, Hennie ^a   Enemuo, Valentine ^c   Stokkers, Pieter C F ^d   Feist, Mark ^e   Bosma, Piter ^a   Jansen, Peter L M ^a   Beuers, Ulrich ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^e Medical Office Building   (United States)

Author keywords

ABCB11; ATP8B1; Cholestasis; Pregnane X receptor; Rifampicin

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; BILE SALT EXPORT PUMP; BILIRUBIN; CLAVULANIC ACID; FLUCLOXACILLIN; PAINT; RIFAMPICIN; ABC TRANSPORTER; ABCB11 PROTEIN, HUMAN; ADENOSINE TRIPHOSPHATASE; ATP8B1 PROTEIN, HUMAN; CARRIER PROTEIN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; CYTOCHROME P450 3A INDUCER; GLUCURONOSYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; ORGANIC SOLUTE TRANSPORTER BETA, HUMAN; PREGNANE X RECEPTOR; STEROID RECEPTOR; UGT1A1 ENZYME;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CHOLESTASIS; CLINICAL ARTICLE; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG ACTIVATION; DRUG ANALYSIS; DRUG DETOXIFICATION; DRUG EFFECT; DRUG TRANSFORMATION; DRUG TRANSPORT; ENTEROHEPATIC CIRCULATION; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE CELL; LIMIT OF QUANTITATION; LIVER CELL; LIVER INJURY; MALE; MIDDLE AGED; PERSISTENT HEPATOCELLULAR SECRETORY FAILURE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SHORT BOWEL SYNDROME; TOTAL PARENTERAL NUTRITION; UPREGULATION; VERY ELDERLY; YOUNG ADULT; ADOLESCENT; AGONISTS; BLOOD; COMPLICATION; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; HEPG2 CELL LINE; HT 29 CELL LINE; LIVER; LIVER FAILURE; METABOLISM; MUTATION; PATHOPHYSIOLOGY; RISK FACTOR; SECRETION (PROCESS); SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADENOSINE TRIPHOSPHATASES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ATP-BINDING CASSETTE TRANSPORTERS; BILIRUBIN; CHOLESTASIS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 CYP3A INDUCERS; DRUG-INDUCED LIVER INJURY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUCURONOSYLTRANSFERASE; HEP G2 CELLS; HT29 CELLS; HUMANS; LIVER; LIVER FAILURE; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MUTATION; RECEPTORS, STEROID; RIFAMPIN; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UP-REGULATION; YOUNG ADULT;

EID: 84940366255     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12603     Document Type: Article

References (35)

1. EASL Clinical Practice Guidelines. Management of cholestatic liver diseases. J Hepatol 2009; 51: 237-67.
2. Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology 2009; 50: 291-308.
3. Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 318-28.
4. Zollner G, Trauner M. Nuclear receptors as therapeutic targets in cholestatic liver diseases. Br J Pharmacol 2009; 156: 7-27.
5. Maillette de Buy Wenniger LJ, Oude Elferink RP, Beuers U. Molecular targets for the treatment of fibrosing cholangiopathies. Clin Pharmacol Ther 2012; 92: 381-7.
6. Seglen PO. Hepatocyte suspensions and cultures as tools in experimental carcinogenesis. J Toxicol Environ Health 1979; 5: 551-60.
7. Kremer AE, Dijk RV, Leckie P, et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin and responds to therapeutic interventions. Hepatology 2012; 56: 1391-1400.
8. Nibourg GA, Huisman MT, van der Hoeven TV, et al. Stable overexpression of pregnane X receptor in HepG2 cells increases its potential for bioartificial liver application. Liver Transpl 2010; 16: 1075-85.
9. Cohen E, Ophir I, Shaul YB. Induced differentiation in HT29, a human colon adenocarcinoma cell line. J Cell Sci 1999; 112(Pt 16): 2657-66.
10. Morotti RA, Suchy FJ, Magid MS. Progressive familial intrahepatic cholestasis (PFIC) type 1, 2, and 3: a review of the liver pathology findings. Semin Liver Dis 2011; 31: 3-10.
11. Folmer DE, van der Mark VA, Ho-Mok KS. Oude Elferink RP, Paulusma CC. Differential effects of progressive familial intrahepatic cholestasis type 1 and benign recurrent intrahepatic cholestasis type 1 mutations on canalicular localization of ATP8B1. Hepatology 2009; 50: 1597-605.
12. Kubitz R, Droge C, Stindt J, Weissenberger K, Haussinger D. The bile salt export pump (BSEP) in health and disease. Clin Res Hepatol Gastroenterol 2012; 36: 536-53.
13. Moghadamrad S, Montani M, Weimann R, De GA. Cholestasis in a patient with gallstones and a normal gamma-glutamyl transferase. Hepatology 2013; 57: 2539-41.
14. Lang C, Meier Y, Stieger B, et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics 2007; 17: 47-60.
15. Meier Y, Zodan T, Lang C, et al. Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump. World J Gastroenterol 2008; 14: 38-45.
16. Enoru-Eta J, Yengi LG, He X, et al. Development of a UGT1A1 reporter gene assay for induction studies: correlation between reporter gene data and regulation of UGT1A1 in human hepatocytes. Drug Metab Lett 2010; 4: 31-8.
17. Luo G, Cunningham M, Kim S, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002; 30: 795-804.
18. Marschall HU, Wagner M, Zollner G, et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005; 129: 476-85.
19. Ballatori N. Pleiotropic functions of the organic solute transporter Ostalpha-Ostbeta. Dig Dis 2011; 29: 13-7.
20. Dawson PA, Hubbert ML, Rao A. Getting the mOST from OST: role of organic solute transporter, OSTalpha-OSTbeta, in bile acid and steroid metabolism. Biochim Biophys Acta 2010; 1801: 994-1004.
21. Boyer JL, Trauner M, Mennone A, et al. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol 2006; 290: G1124-30.
22. Schaap FG, van der Gaag NA, Gouma DJ, Jansen PL. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 2009; 49: 1228-35.
23. Teng S, Jekerle V, Piquette-Miller M. Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab Dispos 2003; 31: 1296-9.
24. Bjornsson E, Ismael S, Nejdet S, Kilander A. Severe jaundice in Sweden in the new millennium: causes, investigations, treatment and prognosis. Scand J Gastroenterol 2003; 38: 86-94.
25. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42: 481-9.
26. Bjornsson E, Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol 2009; 50: 511-7.
27. van der Woerd WL, van Mil SW, Stapelbroek JM, et al. Familial cholestasis: progressive familial intrahepatic cholestasis, benign recurrent intrahepatic cholestasis and intrahepatic cholestasis of pregnancy. Best Pract Res Clin Gastroenterol 2010; 24: 541-53.
28. Stapelbroek JM, van Erpecum KJ, Klomp LW, Houwen RH. Liver disease associated with canalicular transport defects: current and future therapies. J Hepatol 2010; 52: 258-71.
29. di MA, De ME, Ascenzi P, Marino M. Nuclear receptors CAR and PXR: molecular, functional, and biomedical aspects. Mol Aspects Med 2009; 30: 297-343.
30. Staudinger JL, Goodwin B, Jones SA, et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A 2001; 98: 3369-74.
31. Dawson PA, Hubbert M, Haywood J, et al. The heteromeric organic solute transporter alpha-beta, Ostalpha-Ostbeta, is an ileal basolateral bile acid transporter. J Biol Chem 2005; 280: 6960-8.
32. Christian WV, Li N, Hinkle PM, Ballatori N. beta-subunit of the Ostalpha-Ostbeta organic solute transporter is required not only for heterodimerization and trafficking but also for function. J Biol Chem 2012; 287: 21233-43.
33. Li T, Chiang JY. Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7 alpha-hydroxylase gene transcription. Am J Physiol Gastrointest Liver Physiol 2005; 288: G74-84.
34. Bachs L, Pares A, Elena M, Piera C, Rodes J. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992; 102: 2077-80.
35. Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int 2006; 26: 943-8.